COVID-19 COVID-19 Vaccine Pharmaceutical Industry 
Bill of Health
OCTOBER 26, 2023
By Kayum Ahmed, Julia Bleckner, and Kyle Knight In mid-May, the World Health Organization officially declared the “emergency” phase of the COVID-19 pandemic over. This pattern has had lethal consequences during the COVID-19 pandemic, harming efforts to advance global solidarity.
Bill of Health
AUGUST 29, 2022
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. The unprecedented scope of the COVID-19 pandemic quickly gave rise to a surge of pledging activity, which is detailed in this article (see pp. Pandemic Pledges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
DECEMBER 12, 2023
By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines. Impact of the judgment: what have records disclosed shown?
HIT Consultant
MAY 2, 2022
The FDA is attempting to address this, having issued guidelines related to diversity in clinical trials in November 2020 – perhaps prompted by widespread media coverage of the fact that the black members of the society and other people of color were underrepresented in clinical trials for COVID-19 vaccines.
HIT Consultant
MAY 25, 2022
A recent report from the National Institutes of Health projected spending on specialty drugs to outpace growth in the pharmaceutical market, enough to exceed 50 percent of overall drug expenditures in 2021. These drugs bring the promise of positive clinical outcomes where they are most needed, so expanding access to them is imperative.
HIT Consultant
AUGUST 18, 2021
The pandemic has given rise to new norms in drug development that will influence the future of the industry as we know it. The world has been in urgent need of COVID-19 vaccines, treatments, and diagnostic tools. Here’s a look at what we’ve learned from COVID-19 era regulatory practices in clinical development.
HIT Consultant
FEBRUARY 3, 2023
JP Perez-Etchegoyen, CTO of Onapsis Due to the recent growth of the pharmaceutical industry, the value of highly-sensitive data stored in pharmaceutical systems and the degree of the potential damage that cyberattacks on the industry can cause, it is safe to say that pharma could be one of the most targeted industries by cybercriminals in 2023.
Expert insights. Personalized for you.
303 
Let's personalize your content